Awada A - Search Results

1

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.

Thouvenin J, Van Marcke C, Decoster L, Raicevic G, Punie K, Vandenbulcke M, Salgado R, Van Valckenborgh E, Maes B, Joris S, Steichel DV, Vranken K, Jacobs S, Dedeurwaerdere F, Martens G, Devos H, Duhoux FP, Rasschaert M, Pauwels P, Geboes K, Collignon J, Tejpar S, Canon JL, Peeters M, Rutten A, Van de Mooter T, Vermeij J, Schrijvers D, Demey W, Lybaert W, Van Huysse J, Mebis J, Awada A, Claes KBM, Hebrant A, Van der Meulen J, Delafontaine B, Bempt IV, Maetens J, de Hemptinne M, Rottey S, Aftimos P, De Grève J. Thouvenin J, et al. Among authors: awada a. ESMO Open. 2022 Aug;7(4):100524. doi: 10.1016/j.esmoop.2022.100524. Epub 2022 Aug 12. ESMO Open. 2022. PMID: 35970014 Free PMC article.

2

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

Aftimos P, Awada A. Aftimos P, et al. Among authors: awada a. Adv Ther. 2011 Nov;28(11):973-85. doi: 10.1007/s12325-011-0070-9. Epub 2011 Oct 19. Adv Ther. 2011. PMID: 22020735 Review.

3

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Awada A, Vandone AM, Aftimos P. Awada A, et al. Curr Opin Oncol. 2012 May;24(3):297-304. doi: 10.1097/CCO.0b013e3283521349. Curr Opin Oncol. 2012. PMID: 22410457 Review.

4

Targeted therapies of solid cancers: new options, new challenges.

Awada A, Aftimos PG. Awada A, et al. Curr Opin Oncol. 2013 May;25(3):296-304. doi: 10.1097/CCO.0b013e32835ff318. Curr Opin Oncol. 2013. PMID: 23493191 Review.

5

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.

Aftimos PG, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F. Aftimos PG, et al. Among authors: awada a. Int J Oncol. 2013 Sep;43(3):919-26. doi: 10.3892/ijo.2013.2008. Epub 2013 Jul 8. Int J Oncol. 2013. PMID: 23835698

6

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart M, Awada A. Ades F, et al. Among authors: awada a. J Chemother. 2013 Aug;25(4):239-46. doi: 10.1179/1973947813Y.0000000085. J Chemother. 2013. PMID: 23906077

7

Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine.

Aftimos PG, Barthelemy P, Awada A. Aftimos PG, et al. Among authors: awada a. Discov Med. 2014 Feb;17(92):81-91. Discov Med. 2014. PMID: 24534471 Free article. Review.

8

Anticancer drug development: moving away from the old habits.

Ades F, Zardavas D, Aftimos P, Awada A. Ades F, et al. Among authors: awada a. Curr Opin Oncol. 2014 May;26(3):334-9. doi: 10.1097/CCO.0000000000000076. Curr Opin Oncol. 2014. PMID: 24614094 No abstract available.

9

Impact of tumor sequencing on the use of anticancer drugs.

Thomas F, Desmedt C, Aftimos P, Awada A. Thomas F, et al. Among authors: awada a. Curr Opin Oncol. 2014 May;26(3):347-56. doi: 10.1097/CCO.0000000000000078. Curr Opin Oncol. 2014. PMID: 24709974 Review.

10

Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Polastro L, Aftimos PG, Awada A. Polastro L, et al. Among authors: awada a. Expert Rev Anticancer Ther. 2014 Jun;14(6):649-65. doi: 10.1586/14737140.2014.920693. Expert Rev Anticancer Ther. 2014. PMID: 24852360 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

545 results

Search Page